Agios Pharmaceuticals, Inc. · NASDAQ:AGIO
Gheuens Sarah sold 1,989 Agios Pharmaceuticals, Inc. shares (Form 4)
Traded Oct 21 to Oct 22, 2026 · Filed Oct 23, 2026
From Oct 21 to Oct 22, 2026, Gheuens Sarah (Chief Medical Officer) sold 1,989 Agios Pharmaceuticals, Inc. shares at an average US$37.53 for US$74,642 under a trading plan, leaving 54,645 shares. Filed Oct 23, 2026 (Form 4).
- Sold
- 1,989 shares
- Price
- US$37.53 average (US$37.52 to US$37.53)
- Value
- US$74,642
- Holding after
- 54,645 shares
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Chief Medical Officer
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Oct 21, 2026 | Common stock | Option exercise | 1,489 | US$25.01 | 56,134 | Direct |
| Oct 21, 2026 | Common stock | Sale | 1,489 | US$37.53 | 54,645 | Direct |
| Oct 22, 2026 | Common stock | Option exercise | 500 | US$25.01 | 55,145 | Direct |
| Oct 22, 2026 | Common stock | Sale | 500 | US$37.52 | 54,645 | Direct |
Source
Download original · View original at SEC
Related
- Agios Pharmaceuticals, Inc.
- Gheuens Sarah
- Agios Pharmaceuticals, Inc. shareholders
- Form 4 · Gheuens Sarah · Aug 6, 2026
- Form 4 · Gheuens Sarah · Jul 2, 2026
- Form 4 · Gheuens Sarah · Apr 6, 2026
- Schedule 13G/A · Farallon Capital Management, L.L.C. · Aug 3, 2026
- Form 4 · Backstrom Jay T. · Jul 10, 2026
- Schedule 13G · D. E. Shaw & Co., L.P. · Jul 2, 2026
- Form 4 · Ballal Rahul D. · Jun 23, 2026
- Form 4 · Capello Jeffrey D · Jun 23, 2026